Higher Risk of Proteinuria with Atezolizumab plus Bevacizumab than Lenvatinib in First-Line Systemic Treatment for Hepatocellular Carcinoma
Patients treated with Atezo/Bev as first-line systemic treatment for HCC exhibited a higher risk of proteinuria compared with those with LEN, particularly when accompanied by MVI.
Authors
- Han Chu Lee (ORCID: https://orcid.org/0000-0002-7631-4124)
- Jonggi Choi (ORCID: https://orcid.org/0000-0002-7470-5850)
- Danbi Lee (ORCID: https://orcid.org/0000-0002-8336-0006)
- Ju Hyun Shim (ORCID: https://orcid.org/0000-0002-7336-1371)
- Hyung‐Don Kim (ORCID: https://orcid.org/0000-0001-9959-0642)
- Won‐Mook Choi (ORCID: https://orcid.org/0000-0002-9158-1765)
- Young‐Suk Lim (ORCID: https://orcid.org/0000-0002-1544-577X)
- Kang Mo Kim (ORCID: https://orcid.org/0000-0002-3180-3178)
- Changhoon Yoo (ORCID: https://orcid.org/0000-0002-1451-8455)
- Jiwon Yang (ORCID: https://orcid.org/0000-0003-4226-7224)
Institutions
- Ulsan College (KR)
- Asan Medical Center (KR)
- University of Ulsan (KR)
Publication Details
- Journal
- Liver Cancer
- Published
- 2024-10-16
- DOI
- https://doi.org/10.1159/000541621
- Citations
- 1
- Primary Topic
- Hepatocellular Carcinoma Treatment and Prognosis
- Type
- article
- Field-Weighted Citation Impact
- 0.37